protein
| interacting in a positive feedback loop with SHH in mouse limb development and with DHH and IHH in carcinogenesis |
|
PDGFRA |
|
PTCH |
|
GLI1-GLI2 feedback loop in hedgehog-mediated epidermal cell proliferation, binded by its GLI-binding consensus sequence in the promoter (GLI2 directly activates GLI1) |
|
interacting with STK36 |
|
direct transcriptional target of EWS-FLI1 and may have a potential role for GLI1 in Ewing sarcoma family of tumors tumorigenesis |
|
interacting with SUFU and SPOP (SUFU regulates GLI protein levels by antagonizing the activity of SPOP, a conserved GLI-degrading factor) |
|
PIAS1-dependent SUMOylation influences GLI1, GLI2, GLI3 protein activity and thereby identifies SUMOylation as a post-translational mechanism that regulates the hedgehog signaling pathway |
|
interacts with SMARCB1 (localizes to GLI1-regulated promoters and loss of SMARCB1 leads to activation of the HH-GLI pathway) |
|
GNB2L1 suppresses FEM1B pro-apoptotic activity in cancer cells and promote activation of GLI1 activity in cancer cells |
|
play a central role in SHH signaling in prostate cancer, and can act as a co-repressor to substantially block AR-mediated transactivation, at least in part, by directly interacting with AR |
|
directly regulated the transcription of CDH1, a key determinant of epithelial tissue organization |
|
potentially, upon Hedgehog input, GLI1 functions collectively with GLI2 and GLI3 in osteogenesis |
|
enhances the function of GLI1 by increasing its transcriptional activity, nuclear localization and protein stability, but not of GLI2 nor GLI3 |
|
regulatory loop between FERMT2 and GLI1, an effector of Hedgehog signaling pathway (FERMT2 is transcriptionally downregulated via GLI1 occupancy on the FERMT2 promoter) |
|
overexpression of VHL may antagonize Hedgehog-GLI1 activation at the post-translational level in Hedgehog pathway-induced cancers |
|
key role for GLI1 in maintaining the levels of activated STAT3 through the modulation of IL6 signaling |
|
CCND1, a key mediator of cell growth during tissue regeneration, is a GLI1 transcriptional target, binding to the CCND1 promoter and regulating its activity and expression |
|
FEM1B interacts with GLI1 within cells, and directly binds GLI1 (promotes ubiquitylation of GLI1, suppresses transcriptional activation by GLI1, and attenuates an oncogenic GLI1 autoregulatory loop in cancer cells) |
|
GLI1 and GLI2 activated the expression of a basic helix-loop-helix type suppressor BHLHE41 through a GLI-binding site in the promoter |
|
PKD1L1-PKD2L1 acts as a ciliary calcium channel controlling ciliary calcium concentration and thereby modifying SMO-activated GLI2 translocation and GLI1 expression |
|
connection between SHH-GLI1 signaling and S100A4 regulation, which imply that S100A4 might be one of the key factors in EMT mediated by SHH-GLI1 signaling in pancreatic cancer (pMID: 25072505) |
|
GLI1, GLI2, GLI3 interacts synergistically with KIFAP3 and KIF3A |
|
TAF9 interacts with the oncogenic GLI family members GLI1 and GLI2 but not GLI3 |
|
TP53 sequesters TAF9 from GLI1, which may contribute to inhibition of GLI1 activity by TP53 and potentially impact therapeutic success of agents targeting GLI-TAF9 interactions in cancer |
|
GLI1 and GLI2 directly bind to the promoter regions of NEK2 gene and induced its transcription |
|
SENP1 is the specific deSUMOylation enzyme for GLI1 |
|
ITM2A is a strong negative regulator of GLI transcriptional activity and of GLI1 stability |
|
|